Pre-Open Movers 03/24: (GSAT) (NVAX) (CTMX) Higher; (MIST) (BXRX) (HOTH) Lower (more...)

Today's Pre-Open Movers

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) 75.9% LOWER; announced topline results from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of its investigational new drug, etripamil nasal spray, the Company's novel short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

Globalstar, Inc. (NYSE: GSAT) 61% HIGHER; announced that the Third Generation Partnership Project has approved the 5G variant of Globalstar’s Band 53, which will be known as n53.

Novavax, Inc. (NASDAQ: NVAX) 41.3% HIGHER; announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older. Using the Food and Drug Administrations (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone® Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) 41% HIGHER; CytomX and Astellas Pharma Inc. announced they have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer. The parties will utilize CytomX’s Probody® therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.

Vapotherm (NYSE: VAPO) 24% HIGHER; The Company has seen significant increase in demand for Vapotherm Precision Flow® systems and single-use disposables as a result of COVID-19. The Company has been working to materially increase production capacity in its facility in New Hampshire, while ensuring the safety of employees at all times. Vapotherm has increased the number of production shifts and has identified additional opportunities to further increase manufacturing capacity in an effort to keep up with growing demand. This increased production is putting pressure on our supply chain and the Company is working with policy makers and suppliers to increase availability of critical parts to support production at these higher levels.

Genworth Financial, Inc. (NYSE: GNW) 17.8% HIGHER; Genworth and China Oceanwide Holdings Group Co., Ltd. (Oceanwide) today announced that the New York State Department of Financial Services (NYDFS) has reapproved the proposed acquisition of control by Oceanwide of Genworth's New York-domiciled insurance company, Genworth Life Insurance Company of New York (GLICNY). NYDFS' original approval expired in March 2019.

Baudax Bio, Inc. (Nasdaq: BXRX) 17% LOWER; announced that it has commenced an underwritten public offering of its common stock, Series A warrants and Series B warrants. All of the securities in the offering are to be sold by Baudax.

Aytu BioScience, Inc. (NASDAQ: AYTU) 15.5% HIGHER; adds to 37.5% intra-day gain after the company announced that it has received confirmation from the FDA that the company may begin distribution of its Coronavirus Disease 2019 IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.

Hoth Therapeutics Inc. (Nasdaq: HOTH) 12% LOWER; intends to offer shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

CEL-SCI Corporation (NYSE: CVM) 7.9% LOWER; announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 500,000 shares of common stock of the Company, at a price to the public of $12.22 per share, representing a 5% discount to the closing price per share. The closing of the offering is expected to occur on or about March 26, 2020, subject to customary closing conditions.

Prospect Capital (NASDAQ: PSEC) 4% HIGHER; CEO, John Barry, bought 2,145,160 shares on 03/19 at prices from $4.67-$4.86.

Twitter, Inc. (NYSE: TWTR) 1% LOWER; announced the company is withdrawing its revenue and operating income guidance for the first quarter of 2020, as well as its outlook for expenses, stock-based compensation, headcount, and capital expenditures for the full year due to the growing impact of COVID-19 on the global operating and economic environment and their effect on advertiser demand.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Direct Digital Holdings (DRCT) Receives Nasdaq Non-compliance Notice
• Centessa Pharmaceuticals (CNTA) Announces Pricing of $100 Million Public Offering of American Depositary Shares